PDCD1 and non-small cell lung carcinoma: Nonetheless, these trials represent proof-of-concept.135,138 For example, in the PACIFIC trial, over 700 patients with non-small cell lung cancer were randomized to the PD-1 inhibitor durvalumab versus placebo after definitive chemoradiotherapy, and the patients who received ICI demonstrated improved clinical outcomes.139 Trials of ICI and radiation are enrolling a variety of cancer subtypes, and there are ongoing clinical trials of radiation with other immunotherapy approaches, such as a phase II study of radiation plus T-VEC (NCT02819843).